**Supplementary Figure 2. Data Extraction Form**

**Checklist Economic Evaluation**

|  |
| --- |
| **General Part** |
| **Author:** |
| **Title:** |
| **Journal:** |
| **Year of Publication:** |
| **Country:** |
| **Financier:** |
| **Perspective of Analysis:** 0 mentioned  0 society0 health care sector0 insurers0 institutions0 clients0 other, namely…….. | 0 not mentioned**Own assessment of analysis:**0 society0 health care sector0 insurers0 institutions0 clients0 other, namely…….. |
| **Theoretical background of study:** |
| **Short description of Self Management Intervention:** Delivered by who:What:To whom:Where:How often: |
| **Short description of Alternative intervention 1:** Delivered by who:What:To whom:Where:How often: |
| **Short description of Alternative intervention 2:** Delivered by who:What:To whom:Where:How often: |
| **Remarks:** |
| **Follow-up (= time horizon/period of study):** |
| **Disease Category:**0 infectious and parasitic diseases, namely……..0 neoplasm, namely……..0 endocrine, nutritional and metabolic diseases, namely……..0 diseases of blood and blood-forming organs, namely:0 mental disorders, namely……..0 diseases of the nervous system and sens organs, namely……..0 diseases of the circulatory system, namely……..0 diseases of the respiratory system, namely……..0 diseases of the digestive system, namely……..0 diseases of the genitourinary system, namely……..0 childbirth and complications of pregnancy, childbirth and the puerperium, namely……..0 diseases of the skin and subcutaneous tissue, namely……..0 diseases of the musculoskeletal system and connective tissue, namely……..0 congenital anomalies, namely……..0 certain conditions originating in the perinatal period, namely……..0 symptoms, signs and ill-defined conditions, namely……..0 injury and poisoning, namely……..0 other, namely…….. |
| **Epidemiological Part** |
| **Epidemiological design used:**0 experimental/randomized controlled trial 0 observational0 case-control study0 other, namely…….. |
| **Study size (if possible complete each item):**0 N (total number of included participants):0 Number of groups0 N per group |
| **Study population:**0 Prestratification 0 Matching on relevant prognostic factors0 Eligibility criteria (in- and exclusion criteria)0 Homogeneity/Similarity in relevant aspects at baseline0 Documentation of protocol deviations, for example:0 Withdrawals, N per group:Due to:0 Drop-outs, N per group:Due to:0 Contamination, N per group:Due to: 0 Non-compliers, N per group:Due to:1. Co-intervention, N per group:

Due to: |
| **Treatment allocation & treatment**0 Randomization0 Treatment allocation concealed |
| **Adequate measurement and Analysis of effects**0 Patients blinded0 Therapist blinded0 Observer blinded0 Investigator blinded0 Intention-to-treat analysis |
| **Remarks:** |
| **Economical Part** |
| **Economic Evaluation Design Used:**0 Full economic Cost-minimization analysis, costs in monetary terms and effects are assumed equal between interventions 0 Full economic Cost-effectiveness analysis, costs in monetary terms and effects in natural unites (e.g. pain, blood pressure) 0 Full economic Cost-utility analysis, costs in monetary terms and effects in utilities and quality adjusted life years 0 Full economic Cost-benefit analysis, both costs and effects in monetary terms 0 Other, namely…….. |
| **Costs Identification:** | *Health care costs:*0 Hospital visits0 GP visits0 Other, namely…….. | *Patient and family costs:*0 Travel costs0 Cost of informal care0 Other, namely…….. |
| *Cost outside the health care sector:*0 Productivity costs0 Other, namely…….. | *Intervention cost*0 Yes0 No |
| **Costs measurement:**Which sources are used to measure costs (e.g. questionnaire, diary, hospital records)? |
| **Cost valuation:**0 *Valuation of overall costs*0 Tarrifs0 Cost price estimations0 Cost guidelines0 Other, namely……..0 *Valuation of productivity losses*0 Human Capital approach0 Friction Cost method0 US Panel approach |
| **Price year and index**Which price year is chosen:Are other costs indexed0 Yes0 No |
| **Effect identification and measurement:***Characteristic: Instrument:*Depression (example) BDI (example) |
| **Discounting:**0 Costs Percentage………%0 Effects Percentage………%0 Costs and Effects Percentage costs………%  Percentage effects………% |
| **Synthesis costs and effects:**0 ICER (Incremental Cost Effectiveness Ratio)0 NMB (Net Monetary Benefit)0 NET cost (if Cost Benefit Analysis is used)0 Other, namely…….. |
| **Uncertainty:**0 Test sample uncertainty 0 via bootstrap 0 via Fieller0 Test variable uncertainty via sensitivity  0 one-way sensitivity analysis 0 two-way sensitivity analysis 0 multiple sensitivity analysis0 Methodological sensitivity analysis overcome by following a guideline 0 following this guideline:0 Other, namely…….. |
| **Visualization of results:**0 Cost Effectiveness Plane (CE Plane)0 Cost Effectiveness Acceptability Curve (CEAC)0 Other, namely…….. |
| **Main results (in two or three sentences, with numbers - e.g. ICER - if possible):** |
| **Remarks:** |
| **CHEC List** |
| **Item: Yes No** |
| 1. Is the study population clearly described?2. Are competing alternatives clearly described?3. Is a well-defined research question posed in answerable form?4. Is the economic study design appropriate to the stated objective?5. Is the chosen time horizon appropriate to include relevant costs and consequences?6.Is the actual perspective chosen appropriate?7. Are all important and relevant costs for each alternative identified?8. Are all costs measured appropriately in physical units?9. Are costs valued appropriately?10. Are all important and relevant outcomes for each alternative identified?11. Are all outcomes measured appropriately?12. Are outcomes valued appropriately?13. Is an incremental analysis of costs and outcomes of alternatives performed?14. Are all future costs and outcomes discounted appropriately?15. Are all important variables, whose values are uncertain, appropriately subjected to sensitivity analysis?16. Do the conclusions follow from the data reported?17. Does the study discuss the generalizability of the results to other settings and patient/ client groups?18. Does the article indicate that there is no potential conflict of interest of study researcher(s) and funder(s)?19. Are ethical and distributional issues discussed appropriately? |  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0  0 0 |